Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30377833 | 1.00 | DRD2 (0.47) | DRD2DRD3PARP1HTR1AHTR2C | |
| SCHEMBL405139 | 0.95 | DRD2 (0.48) | DRD2DRD3PARP1HTR1AHTR2C | |
| SCHEMBL401463 | 0.87 | DRD2 (0.50) | DRD2DRD3PARP1HTR1AHTR3A | |
| SCHEMBL7478192 | 0.73 | PARP1 (0.52) | DRD2DRD3PARP1HTR1AHTR2C | |
| SCHEMBL9204124 | 0.72 | DRD2 (0.57) | DRD2DRD3PARP1HTR1AHTR3A | |
| SCHEMBL9124998 | 0.71 | DRD2 (0.56) | DRD2DRD3PARP1HTR1AHTR3A | |
| SCHEMBL2266482 | 0.68 | PARP1 (0.41) | PARP1HTR1AHTR2CHTR2AHTR3A | |
| SCHEMBL854184 | 0.68 | PARP1 (0.61) | DRD2DRD3PARP1HTR1AHTR3A | |
| SCHEMBL14716992 | 0.68 | TSHR (0.34) | HTR2CHTR2AHSD17B10TSHRBCL2L1 | |
| SCHEMBL12037714 | 0.67 | PARP1 (0.41) | PARP1HTR1AHTR2CHTR2AHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071421-B2 | Process for the synthesis of substituted chloromethyl dialkylphosphates | HELSINN HEALTHCARE SA (CH) | 2024-08-27 | — | — | US | disclosed |
| CN-111662330-B | Substituted 4-phenylpyridines for the treatment of NK-1 receptor related diseases | 赫尔森保健股份公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20220401463-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | HELSINN HEALTHCARE SA (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11312698-B2 | Fosnetupitant chloride hydrochloride having improved stability | HELSINN HEALTHCARE SA (CH) | 2022-04-26 | — | — | US | disclosed |
| US-20200399240-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | HELSINN HEALTHCARE SA (CH) | 2020-12-24 | — | — | US | disclosed |
| US-10717721-B2 | Substituted piperaziniums for the treatment of emesis | HELSINN HEALTHCARE SA (CH) | 2020-07-21 | — | — | US | disclosed |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA | 2019-09-10 | — | — | US | disclosed |
| EP-3181133-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190177296-A1 | SOLUTION COMPRISING THE CHLORIDE HYDROCHLORIDE SALT OF 4-(5-(2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-N,2-DIMETHYLPROPANAMIDO)-4-(o-TOLYL)PYRIDIN-2-YL)-1-METHYL-1-((PHOSPHONOOXY)METHYL)PIPERAZIN-1-IUM (FOSNETUPITANT) AND PALONOSETRON HYDROCHLORIDE IN COMBINATION WITH DEXAMETHASONE AS A NEUROKININ RECEPTOR MODULATOR | HELSINN HEALTHCARE SA (CH) | 2019-06-13 | — | — | US | disclosed |
| US-10208073-B2 | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator | HELSINN HEALTHCARE SA (CH) | 2019-02-19 | — | — | US | disclosed |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| WO-2009136350-A1 | NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009081259-A1 | PHENOXY-PYRIDYL DERIVATIVES | PFIZER INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | DRD2 2308/4885DRD3 2334/4885PARP1 3593/4885 |
| US-11312698-B2 | Fosnetupitant chloride hydrochloride having improved stability | FOS, FOSB, CLCN2 | DRD2 1030/4885DRD3 1640/4885PARP1 2702/4885 |
| US-20200399240-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | BDKRB2, BDKRB1, TACR1 | DRD2 1942/4885DRD3 2195/4885PARP1 3342/4885 |
| US-20220401463-A1 | SUBSTITUTED 4-PHENYL-PYRIDINES | BDKRB2, BDKRB1, TACR1 | DRD2 1942/4885DRD3 2195/4885PARP1 3342/4885 |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | DRD2 1547/4885DRD3 1991/4885PARP1 4149/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | DRD2 1974/4885DRD3 2415/4885PARP1 3348/4885 |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | UTS2R, GPR119, GHSR | DRD2 3566/4885DRD3 3495/4885PARP1 4790/4885 |
| US-12071421-B2 | Process for the synthesis of substituted chloromethyl dialkylphosphates | BDKRB1, BDKRB2, TK1 | DRD2 2109/4885DRD3 2314/4885PARP1 918/4885 |
| US-20190177296-A1 | SOLUTION COMPRISING THE CHLORIDE HYDROCHLORIDE SALT OF 4-(5-(2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-N,2-DIMETHYLPROPANAMIDO)-4-(o-TOLYL)PYRIDIN-2-YL)-1-METHYL-1-((PHOSPHONOOXY)METHYL)PIPERAZIN-1-IUM (FOSNETUPITANT) AND PALONOSETRON HYDROCHLORIDE IN COMBINATION WITH DEXAMETHASONE AS A NEUROKININ RECEPTOR MODULATOR | NR3C2, NR3C1, OPRM1 | DRD2 745/4885DRD3 979/4885PARP1 2726/4885 |
| US-10717721-B2 | Substituted piperaziniums for the treatment of emesis | VIPR2, VIPR1, GRPR | DRD2 1264/4885DRD3 2280/4885PARP1 3131/4885 |
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | DRD2 1044/4885DRD3 1402/4885PARP1 3216/4885 |
| US-10208073-B2 | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator | OPRM1, MC2R, NR3C1 | DRD2 369/4885DRD3 663/4885PARP1 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.